May 17th 2024
"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Available Rectal Spacer Options for Patients With Prostate Cancer Undergoing Radiation Therapy
November 7th 2023Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term clinical data on patient outcomes.
Overcoming Barriers to Triplet Therapy in Prostate Cancer
November 1st 2023Join experts David Morris, MD, FACS, and Benjamin Garmezy, MD, as they discuss the barriers and considerations in prescribing triplet therapy, offering insight into its benefits and how collaborative care between urologists and medical oncologists ensures a seamless patient journey.
Enhancing Efficacy in Advanced Hormone-Sensitive Prostate Cancer Treatment
November 1st 2023Join key opinion leaders as they analyze the evolving landscape of metastatic HSPC, delving into the advantages and key factors to consider with triplet combination therapies, encompassing chemotherapy and ARPI agents.
Common Adverse Effects in Patients With Prostate Cancer Undergoing Radiation Therapy
October 31st 2023Dr Daniel Allan Hamstra discusses common adverse reactions in patients with prostate cancer undergoing radiation therapy, including urinary issues and sexual side effects, and explains the potential impact of rectal spacer devices like SpaceOAR in addressing these concerns.
Differences in health care access may drive prostate cancer disparities
October 31st 2023“It was interesting to find that when Black and White men were provided equal access to the same therapies, given at the same dosage and monitored in the same setting, disparities in outcomes were eliminated," says Jun Gong, MD.
Enzalutamide data published in NEJM as FDA weighs nonmetastatic HSPC approval
October 20th 2023The phase 3 EMBARK trial showed that enzalutamide plus leuprolide reduced the risk of metastasis or death by nearly 60% vs leuprolide alone in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
Choosing Partners in Cancer Care: A Strategic Approach
October 20th 2023Delve into the strategic process of selecting ideal partners in cancer care as key opinion leaders share insights on building trust, effective communication, and optimizing patient outcomes through collaborative decision making.
Expert on prostate cancer drug cost savings with the Inflation Reduction Act
October 17th 2023"Hopefully this law will allow more patients with advanced prostate cancer to gain access to these medications, and to take it without substantially changing the quality of their life when it comes to financial consequences," says Benjamin Pockros, MD.
Dr. Samuel Washington III on setting patient expectations after prostate cancer treatment
October 16th 2023"Hopefully this gives patients and providers information that they can use to inform and set reasonable expectations of what patient's lives will look like after treatment," says Samuel L. Washington III, MD, MAS.